Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.

about

Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.

Item

http://www.wikidata.org/entity/Q38689012

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Estimated medical expenditure ...... wo randomized clinical trials.

@en

type

Item

label

Estimated medical expenditure ...... wo randomized clinical trials.

@en

prefLabel

Estimated medical expenditure ...... wo randomized clinical trials.

@en

P1476

Estimated medical expenditure ...... wo randomized clinical trials.

@en

P2093

Amitabh Singh

http://www.w3.org/2001/XMLSchema#string

Bethany E Wilkinson

http://www.w3.org/2001/XMLSchema#string

Charles A Mebus

http://www.w3.org/2001/XMLSchema#string

Gene V Wallenstein

http://www.w3.org/2001/XMLSchema#string

Mark Kosinski

http://www.w3.org/2001/XMLSchema#string

Regina Rendas-Baum

http://www.w3.org/2001/XMLSchema#string

P2860

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS).

Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease.

Epidemiology and burden of illness of rheumatoid arthritis.

Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys.

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.

Generic quality-of-life assessment in rheumatoid arthritis.

P304

1386-1394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEX087

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28460083

http://www.w3.org/2001/XMLSchema#string

P932

5850117

http://www.w3.org/2001/XMLSchema#string